Skip to content

What the HHT?

A blog for the HHT community

2025 HHT Patient and Physician National Conference

2025 HHT Patient and Physician National Conference November 8-9, 2025 Mark your calendars and get ready to join us for the 2025 HHT Patient and Physician National Conference hosted in Dallas, Texas! Details: Two-day event will bring together HHT experts, patients, and healthcare professionals Sessions will share insights about the patient journey as well as…

Read More

This Landmark HHT Study Could Shift National Attention

We’re excited to share some truly important news for the HHT community. A major new study done in collaboration between Cure HHT, Massachusetts General Hospital, and Diagonal Therapeutics — just published in the American Journal of Hematology — delivers something we’ve never had before: hard data that proves HHT is a serious, high-impact disease that’s…

Read More

A Major Step Forward for HHT Treatment: Promising Preclinical Data from Diagonal Therapeutics

We’re excited to share two important updates from our partners at Diagonal Therapeutics. At this week’s European Hematology Association (EHA) Congress, Diagonal Therapeutics presented promising preclinical data demonstrating the potential of their antibody approach to address key challenges in HHT disease manifestations: Restoring ALK1-mediated cellular signaling Preventing and reversing arteriovenous malformations Preventing HHT-associated anemia And just recently…

Read More

Beyond: Looking at the Diverse Faces of HHT

Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder that, despite being present from birth, often goes undiagnosed for many years. A common scenario involves a family member receiving a diagnosis, which then prompts others to seek testing. Even without genetic confirmation, a clinical diagnosis can be made based on characteristic symptoms. The variability in how…

Read More
Scroll To Top